Literature DB >> 1253632

Fosfomycin in Osteomyelitis.

J E Fernandez-Valencia, T Saban, T Cañedo, T Olay.   

Abstract

Fosfomycin was exclusively used as antibiotic treatment in 37 patients suffering from osteomyelitis, out ot which 23 were operated for sequestrectomy or fistulectomy, whereas the remaining 14 did not undergo any surgery during fosfomycin treatment. Fosfomycin was adminsitered parenterally, alone or combined with oral administration, and in some cases only orally. The dosage varied from 4 to 8 g/day for an average period of 3 weeks. After one or two treatments the results were 29 definitive cures (78%), 2 failures and 6 relapses (22%).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1253632     DOI: 10.1159/000221921

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

Review 2.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

3.  Adjuvant fosfomycin medication in chronic osteomyelitis.

Authors:  A Meissner; R Haag; R Rahmanzadeh
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

4.  Fosfomycin for the initial treatment of acute haematogenous osteomyelitis.

Authors:  N Corti; F H Sennhauser; U G Stauffer; D Nadal
Journal:  Arch Dis Child       Date:  2003-06       Impact factor: 3.791

5.  Cure of Limb-Threatening XDR Pseudomonas aeruginosa Infection: Combining Genome Sequencing, Therapeutic Drug Level Monitoring, and Surgical Debridement.

Authors:  Shanti Narayanasamy; Roger L Nation; Andrew A Mahony; M Lindsay Grayson; Jason C Kwong; Norelle L Sherry; Sharmila Khumra; Andrew G Ellis; Albert G Frauman; Natasha E Holmes
Journal:  Open Forum Infect Dis       Date:  2020-11-26       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.